$9.58
-0.52 (-5.10%)
Open$9.86
Previous Close$10.10
Day High$10.09
Day Low$8.73
52W High$31.00
52W Low$5.61
Volume—
Avg Volume125.8K
Market Cap17.53M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+38.5% upside
Current
$9.58
$9.58
Target
$13.27
$13.27
$11.80
$13.27 avg
$20.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.74M | 18.13M | 17.61M |
| Net Income | 675.0K | 507.1K | 519.2K |
| Profit Margin | 3.4% | 2.8% | 3.0% |
| EBITDA | 1.03M | 911.5K | 901.4K |
| Free Cash Flow | 725.0K | 739.6K | 699.1K |
| Rev Growth | -5.2% | +2.0% | -8.0% |
| Debt/Equity | 1.19 | 0.81 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |